28 INOVIQ Limited A Short-Term Incentive (STI) bonus of $70,790 was paid during the financial year for the achievement of agreed key performance indicators (KPIs) for the 12 months to 30 June 2021. The KPIs achieved included (i) successful completion of a significant capital raising, (ii) operational cost savings achieved following the merger with Sienna Cancer Diagnostics Ltd, (iii) product development milestones for EXO-NET and SubB2M, and (iv) research collaborations secured for new technology applications. This STI was paid in October 2021. Dr Hinch may also be eligible for a Long-Term Incentive (LTI), being the grant of options. No options were issued to Dr Hinch during the financial year. Mr Johnston and Mr Powell Mr Max Johnston andMr Philip Powell have Letters of Agreement with the Company dated 17 June 2019 to perform the role of Non-Executive Director for an annual base fee of $50,000 plus superannuation entitlement. Both Directors are not entitled to a termination or redundancy benefit. Professor Cripps Professor Allan Cripps has a Letter of Agreement with the Company dated 23 January 2020 to perform the role of NonExecutive Director for an annual base fee of $50,000 plus superannuation entitlement. Professor Cripps is not entitled to a termination or redundancy benefit. Dr Greg Rice (appointed 20 September 2021) Dr Greg Rice has an Employment Agreement with the Company dated 20 September 2021 to perform the role of Chief Scientific Officer of the Group for an annual base salary of $250,000 per annum plus superannuation entitlement. This arrangement can be terminated by either party providing 1 months written notice within the first 6 months and then 3 months written notice thereafter, which based on current remuneration rates would amount to a termination payment of up to $62,500 if the full notice period is not served. Mr Di Pietro (appointed 28 July 2020) Mr Tony Di Pietro has an Employment Agreement with theGroup dated 23 February 2015 to perform the role of Chief Financial Officer andCompany Secretary, under whichMr Di Pietro is paid a total fixed remuneration of $256,432 per annumplus superannuation entitlement. This arrangement can be terminated by either party providing 3months written notice, which based on current remuneration rates would amount to a termination payment of $64,108 if the full notice period is not served. A Short-Term Incentive (STI) bonus of $27,857 was paid during the financial year for the achievement of agreed key performance indicators (KPIs) for the 12 months to 30 June 2021. The KPIs achieved included (i) successful completion of a significant capital raising, (ii) operational cost savings following the merger with Sienna Cancer Diagnostics Ltd, (iii) product development milestones for EXO-NET and SubB2M, and (iv) research collaborations secured for new technology applications. This STI was paid in October 2021. Mr Di Pietro may also be eligible for a Long-Term Incentive (LTI), being the grant of options. No options were issued to Tony during the financial year. Dr French (appointed 17 August 2020, resigned 17 August 2021) Dr Peter French had an Employment Agreement with the Company dated 17 August 2020 to perform the role of Chief Scientific Officer (CSO) of the Group for an annual base salary of $255,000 per annum plus superannuation entitlement. Dr French resigned on 17 August 2021 and transitioned to the role of Strategic Technology Advisor under a consultancy agreement. This agreement ceased in July 2022. Mr Stubbings (appointed 28 July 2020, resigned 31 August 2021) Mr Carl Stubbings had an Employment Agreement with the Company dated 28 July 2020 to perform the role of Chief Operating Officer for an annual base salary of $255,000 per annum plus superannuation entitlement. At the date of this report the Company does not have any other consultancy or employment agreements in place with KMP. Directors’ Report
RkJQdWJsaXNoZXIy MjE2NDg3